NZ624068A - Fused tricyclic compounds as raf kinase inhibitors - Google Patents
Fused tricyclic compounds as raf kinase inhibitorsInfo
- Publication number
- NZ624068A NZ624068A NZ624068A NZ62406811A NZ624068A NZ 624068 A NZ624068 A NZ 624068A NZ 624068 A NZ624068 A NZ 624068A NZ 62406811 A NZ62406811 A NZ 62406811A NZ 624068 A NZ624068 A NZ 624068A
- Authority
- NZ
- New Zealand
- Prior art keywords
- raf kinase
- fused tricyclic
- compounds
- kinase inhibitors
- tricyclic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085146 WO2013097224A1 (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ624068A true NZ624068A (en) | 2016-09-30 |
Family
ID=48696279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ624068A NZ624068A (en) | 2011-12-31 | 2011-12-31 | Fused tricyclic compounds as raf kinase inhibitors |
Country Status (28)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2797888T1 (sl) | 2011-12-31 | 2017-01-31 | BeiGene, Ltd. Mourant Ozannes Corporate Services (Cayman) Limited | Zlite triciklične spojine kot inhibitorji kinaze raf |
| SG11201600147TA (en) | 2013-06-28 | 2016-02-26 | Beigene Ltd | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2015089809A1 (en) * | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| WO2015176267A1 (en) * | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
| EA035680B1 (ru) * | 2015-04-15 | 2020-07-24 | Бейджин, Лтд. | Малеатные соли ингибитора braf киназы, кристаллические формы, способы их получения и применения |
| JP6175519B2 (ja) * | 2016-01-04 | 2017-08-09 | ベイジーン リミテッド | Ｒａｆキナーゼ阻害剤としての縮合三環式化合物 |
| WO2018007885A1 (en) * | 2016-07-05 | 2018-01-11 | Beigene, Ltd. | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |
| CN110291087B (zh) | 2016-12-01 | 2024-07-09 | 阿尔维纳斯运营股份有限公司 | 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US10723717B2 (en) * | 2016-12-23 | 2020-07-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CN111184693B (zh) * | 2019-05-29 | 2023-07-21 | 百济神州(苏州)生物科技有限公司 | 一种raf激酶抑制剂制剂及其制备方法 |
| KR20220054347A (ko) | 2019-08-26 | 2022-05-02 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법 |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| MX2023001275A (es) | 2020-07-28 | 2023-04-24 | Jazz Pharmaceuticals Ireland Ltd | Inhibidores de raf biciclicos fusionados y metodos para su uso. |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AR123492A1 (es) | 2020-09-14 | 2022-12-07 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno |
| US20240140944A1 (en) * | 2020-12-29 | 2024-05-02 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| WO2023049060A1 (en) * | 2021-09-21 | 2023-03-30 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
| WO2023209611A1 (en) | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| WO2023212071A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Combination and the use thereof |
| WO2024054591A1 (en) | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003245700A1 (en) | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| SI1696920T1 (sl) | 2003-12-19 | 2015-02-27 | Plexxikon Inc. | Spojine in postopki za razvoj modulatorjev ret |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| WO2007013896A2 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| EP1902056A2 (en) | 2005-05-20 | 2008-03-26 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| BRPI0615781A2 (pt) | 2005-09-01 | 2009-06-16 | Array Biopharma Inc | compostos inibidores de raf e métodos de uso destes |
| AU2006322094A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| ATE552245T1 (de) | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| MX2009001913A (es) * | 2006-08-23 | 2009-03-06 | Pfizer Prod Inc | Compuestos de pirimidona como inhibidores de gsk-3. |
| MX2009002010A (es) | 2006-09-06 | 2009-03-05 | Hoffmann La Roche | Derivados de heteroarilo como inhibidores de la proteina cinasa. |
| WO2008030448A1 (en) | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| US20100184791A1 (en) * | 2007-05-04 | 2010-07-22 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| US20100197924A1 (en) * | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| SI2797888T1 (sl) | 2011-12-31 | 2017-01-31 | BeiGene, Ltd. Mourant Ozannes Corporate Services (Cayman) Limited | Zlite triciklične spojine kot inhibitorji kinaze raf |
| EA035680B1 (ru) | 2015-04-15 | 2020-07-24 | Бейджин, Лтд. | Малеатные соли ингибитора braf киназы, кристаллические формы, способы их получения и применения |
-
2011
- 2011-12-31 SI SI201130852A patent/SI2797888T1/sl unknown
- 2011-12-31 CN CN201180069798.XA patent/CN103596926B/zh active Active
- 2011-12-31 DK DK11879096.3T patent/DK2797888T3/en active
- 2011-12-31 HU HUE11879096A patent/HUE029656T2/en unknown
- 2011-12-31 EP EP11879096.3A patent/EP2797888B1/en active Active
- 2011-12-31 AU AU2011384857A patent/AU2011384857B2/en active Active
- 2011-12-31 ME MEP-2016-172A patent/ME02529B/me unknown
- 2011-12-31 HR HRP20160641TT patent/HRP20160641T1/hr unknown
- 2011-12-31 JP JP2014549294A patent/JP5868521B2/ja active Active
- 2011-12-31 PL PL11879096.3T patent/PL2797888T3/pl unknown
- 2011-12-31 MX MX2014007829A patent/MX352617B/es active IP Right Grant
- 2011-12-31 LT LTEP11879096.3T patent/LT2797888T/lt unknown
- 2011-12-31 EP EP16167542.6A patent/EP3124472B1/en active Active
- 2011-12-31 ES ES11879096.3T patent/ES2588775T3/es active Active
- 2011-12-31 RS RS20160713A patent/RS55196B1/sr unknown
- 2011-12-31 KR KR1020147018101A patent/KR101713391B1/ko active Active
- 2011-12-31 US US14/369,379 patent/US9273046B2/en active Active
- 2011-12-31 SG SG11201401725SA patent/SG11201401725SA/en unknown
- 2011-12-31 IN IN6166DEN2014 patent/IN2014DN06166A/en unknown
- 2011-12-31 NZ NZ624068A patent/NZ624068A/en unknown
- 2011-12-31 EA EA201491305A patent/EA025597B1/ru not_active IP Right Cessation
- 2011-12-31 PT PT118790963T patent/PT2797888T/pt unknown
- 2011-12-31 WO PCT/CN2011/085146 patent/WO2013097224A1/en not_active Ceased
- 2011-12-31 BR BR112014013108-2A patent/BR112014013108B1/pt active IP Right Grant
- 2011-12-31 CA CA2856347A patent/CA2856347C/en active Active
-
2014
- 2014-06-25 IL IL233364A patent/IL233364A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05555A patent/ZA201405555B/en unknown
-
2016
- 2016-01-22 US US15/004,311 patent/US9895376B2/en active Active
- 2016-09-05 CY CY20161100869T patent/CY1118226T1/el unknown
- 2016-09-06 SM SM201600302T patent/SMT201600302B/it unknown
-
2018
- 2018-01-29 US US15/882,064 patent/US10576087B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ624068A (en) | Fused tricyclic compounds as raf kinase inhibitors | |
| EA201071234A1 (ru) | Производные изохинолинона в качестве nk3 антагонистов | |
| PT2857404T (pt) | Derivados de imidazo[1,2-b]piridazina como inibidores da cinase | |
| MX2010010317A (es) | Compuestos heterociclicos novedosos y usos de los mismos. | |
| MX342309B (es) | Derivados de [1,2,3]traizolo[4,5-d]pirimidina como agonistas del receptor canabinoide 2. | |
| MX2014013090A (es) | Derivados de pirrolotriazinona. | |
| MX362939B (es) | Derivados de (aza-)isoquinolinona. | |
| TW201129565A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| NZ624063A (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| AU2011278832A8 (en) | Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors | |
| SI2646432T1 (sl) | Substituirani derivati benzopirazina kot inhibitorji FGFR kinaz za zdravljenje rakavih bolezni | |
| EP3097096A4 (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1- (arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation | |
| MX353806B (es) | Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| MX354021B (es) | Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona. | |
| GEP201706691B (en) | Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1 | |
| NZ749557A (en) | 3-alkyl-5-fluoro-4-substituted-imino-3,4-dihydropyrimidin-2(1h)-one derivatives as fungicides | |
| EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
| MX362855B (es) | Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp). | |
| PH12014501026A1 (en) | [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists | |
| CL2011001947A1 (es) | Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular. | |
| PH12015500345A1 (en) | Amino-quinolines as kinase inhibitors | |
| MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
| NZ627558A (en) | Heterocyclic piperidine compounds and methods of their use | |
| NZ594186A (en) | Indole derivatives as anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 31 DEC 2018 BY GRIFFITH HACK Effective date: 20170224 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2019 BY ACUMASS Effective date: 20181119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2020 BY ACUMASS Effective date: 20191120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2021 BY ACUMASS Effective date: 20201118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2022 BY ACUMASS Effective date: 20211122 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2023 BY ACUMASS Effective date: 20221118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2024 BY ACUMASS Effective date: 20231121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2025 BY IPAN GMBH Effective date: 20241210 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 DEC 2026 BY CLARIVATE IP SERVICES LIMITED Effective date: 20251210 |